Participated · Equity · May 2023

OASYS NOW offers an AI-powered clinical-trial patient identification and recruitment platform that meta-crawls trial criteria and cross-matches them with EHRs to find eligible patients. Its two main products are the GRIP app, which gives individuals control of their health data and trial discovery, and the ELaiGIBLE Platform, which lets hospitals, clinics and CROs identify eligible cohorts in minutes. The company focuses initially on cardiology, rare diseases and multiple chronic conditions and has expanded into brain-related diseases (Alzheimer's, Parkinson's, dementia) and immunology. Its systems are built privacy-by-design, are GDPR compliant, and an external party continuously monitors ISO27001 compliance. OASYS NOW is developing a third product using confidential federated learning to enable genetic researchers to collaborate on large datasets without moving the data. The team has drawn interest from NVIDIA and Google as validation for its privacy-first approach. OASYS NOW builds privacy-first cybersecurity, intelligent data storage, and analysis solutions for the health and genomics sector. Its software platform uses blockchain to let people manage consent, control who accesses their health and DNA data, and potentially profit from research participation. The company works with health testing companies, disease research foundations, and academic medical centres to enable secure data sharing for clinical trials and personalised medicine. Founded in 2018 in Delft, OASYS NOW aims to accelerate implementation of medical research and therapies by giving citizens direct control over their data. The startup said it will use recent funding to expand its team and accelerate development of its services to broaden access to personalised medicine globally. Financially, it has just completed a €250K funding round from a mix of VCs and angel investors.

Led · Seed · Nov 2022

Biotic produces bio-based alternatives to fossil-based plastics, manufacturing thermoplastic polymers that span applications from very flexible to very ruggedized products. Its process extracts the carbon source from macroalgae, a biomass grown in every ocean year-round. The company highlights environmental benefits from macroalgae in terms of CO2 impact, and says the feedstock is free of endotoxins and does not compete with arable land. Biotic uses saline water in its process, which it says reduces energy consumption and contamination risks. Led by CEO Adi Goldman, the company intends to use funding to build a plant, optimize processes, and increase production capacity. Financially, Biotic completed a €2M seed financing to support those plans.